Laurence J. DiNardo, MD, FACS, discusses ctDNA testing in head and neck cancers, advancements in targeted therapies, and multidisciplinary collaboration.
Commentary|Videos|March 3, 2026
Dr Pearson on Daily Applications of AI in Clinical Practice
Author(s)Alexander T. Pearson, MD, PhD
Fact checked by: Kyle Doherty
Alexander T. Pearson, MD, PhD, discusses how he uses AI in his current daily practice.
Advertisement
Alexander T. Pearson, MD, PhD, outlines AI tools that he uses in his current practice, including ambient dictation. He emphasizes how this technology enables him to focus on interactions with patients rather than meticulous note taking while still being able to achieve digestible and accurate notes of the visit.
Advertisement
Related to this article
Marina Chiara Garassino, MD, provided a review of AI-designed drugs, autonomous clinical agents, and prescreening devices.
Roswell Park Comprehensive Cancer Center received a grant to advance CAR T-cell therapy research in pediatric AML.
The FDA approved SimpleScreen CRC as a screening option for colorectal cancer in adults 45 years of age and older at average risk for the disease.
Sonesitatug vedotin improved overall survival in pretreated CLDN18.2-positive advanced gastric/GEJ cancers in the phase 3 CLARITY-Gastric01 trial.
Safusidenib produced a 51.9% confirmed ORR and a 79.1% 36-month PFS rate in chemotherapy- and radiotherapy-naive grade 2 IDH1-mutant glioma.
Faculty convened at an OncLive Scientific Interchange and Workshop to discuss individualizing ARPI-based therapy in advanced prostate cancer.
The top 5 OncLive TV videos of the week cover insights in pancreatic cancer, non–small cell lung cancer, the cost and value of immunotherapy, and bladder cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Average-Risk Adults
2
Sonesitatug Vedotin Improves Overall Survival in Second- and Later-Line CLDN18.2-Positive Gastric/GEJ Cancer
3
Volume, Biomarkers, and Cost Realities Guide ARPI Sequencing in Advanced Prostate Cancer
4
Updated Safusidenib Data Show Durable Responses in Grade 2 IDH1-Mutant Glioma
5